119 research outputs found
The New Republic A Commentary on Book I of More's Utopia Showing Its Relation to Plato's Republic
No full textColin Starnes radical interpretation of the long-recognized affinity of Thomas More's Utopia and Plato's Republic confirms the intrinsic links between the two works. Through commentary on More's own introduction to Book I, the author shows the Republic is everywhere present as the model of the "best commonwealth," which More must first discredit as the root cause of the dreadful evils in the collapsing political situation of sixteenth-century Europe. Starnes demonstrates how More, once having shorn the Republic of what was applicable to a society that had for a thousand years accepted and been moved by the Christian revelation, then "Christianized" it to arrive at one of the earliest and most coherent accounts of the ideal modern state: the description of Utopia in Book II. Knowing this radically new view of a long-recognized position may be questioned, the author has included a criticism and appreciation of the other major lines of interpretation concerning More's Utopia.Intro -- Contents -- Author's Note -- Preface -- Notes -- Introduction -- Notes -- Commentary on Book I of More's Utopia -- I. More's Criticism of the Platonic Separation of the Classes -- II. More's Criticism of the Platonic Doctrine of the Philosopher/King -- Notes -- Conclusion -- Notes -- Appendix -- Bibliography -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- J -- K -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U -- V -- W -- XColin Starnes radical interpretation of the long-recognized affinity of Thomas More's Utopia and Plato's Republic confirms the intrinsic links between the two works. Through commentary on More's own introduction to Book I, the author shows the Republic is everywhere present as the model of the "best commonwealth," which More must first discredit as the root cause of the dreadful evils in the collapsing political situation of sixteenth-century Europe. Starnes demonstrates how More, once having shorn the Republic of what was applicable to a society that had for a thousand years accepted and been moved by the Christian revelation, then "Christianized" it to arrive at one of the earliest and most coherent accounts of the ideal modern state: the description of Utopia in Book II. Knowing this radically new view of a long-recognized position may be questioned, the author has included a criticism and appreciation of the other major lines of interpretation concerning More's Utopia.Description based on publisher supplied metadata and other sources.Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, YYYY. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
Priacanthus alalaua Jordan & Evermann 1903
No full textPriacanthus alalaua Jordan & Evermann, 1903. Alalaua or Hawaiian Bigeye. To 32 cm (13 in) TL (Starnes in Carpenter and Niem 1999). Isla Guadalupe (Reyes-Bonilla et al. 2010); Rocas Alijos, southern Baja California; Islas Revillagigedo; Hawai’i; perhaps in other eastern Pacific sites (Starnes 1988). Depth: 9–296 m (30–971 ft) (min.: Starnes in Fischer et al. 1995; max.: Mundy 2005).Published as part of Love, Milton S., Bizzarro, Joseph J., Cornthwaite, Maria, Frable, Benjamin W. & Maslenikov, Katherine P., 2021, Checklist of marine and estuarine fishes from the Alaska-Yukon Border, Beaufort Sea, to Cabo San Lucas, Mexico, pp. 1-285 in Zootaxa 5053 (1) on page 150, DOI: 10.11646/zootaxa.5053.1.1, http://zenodo.org/record/557800
Physician-modified endovascular grafts for the treatment of elective, symptomatic, or ruptured juxtarenal aortic aneurysms
No full textObjectiveTo determine if a physician-modified endovascular graft (PMEG) is a safe and effective method of treating juxtarenal aortic aneurysms in patients considered to be unsuitable for open surgical repair.MethodsA retrospective, nonrandomized, single institution evaluation of the safety and efficacy of physician modification of a currently Food and Drug Administration-approved device (Zenith Flex; Cook Inc, Bloomington, Ind) to preserve branch vessels when used in the treatment of patients with elective, symptomatic, or ruptured juxtarenal aortic aneurysms.ResultsForty-seven consecutive patients underwent fenestrated endovascular repair using PMEG over a 3-year period. Thirty-eight patients (80%) were symptomatic or had rapid aneurysm expansion. Eighty-five percent of patients were American Society of Anesthesiologist category III or IV. Eight-two fenestrations were created for 58 renal arteries, 16 superior mesenteric arteries, three celiac arteries, and the rest accessory vessels. Mean follow-up was 607 days, with a range of 425 to 1460 days. Mean contrast usage and fluoro time were 98 mL and 48 minutes. Technical success rate was 98%, and freedom from aneurysm-related death was 98%. There were six complications (13%). Three (6%) were access related, and three (6%) were procedure related and included one stroke, one case of renal failure, and one branch artery dissection. On follow-up, six patients (13%) had endoleak. There was one type 1 endoleak and five type 2 endoleaks. In-hospital and 30-day mortality was 2%, with one patient expiring due to aspiration on the ward after successful endovascular repair. Two patients died during follow-up; one at 58 days due to cessation of dialysis and one at 485 days due to stent graft migration and occlusion of the superior mesenteric artery. There were two deaths in the first year, one in the second year, and zero in the most recent year of experience. One patient with endoleak (2%) had aneurysm sac expansion at 1 year requiring secondary intervention.ConclusionsPMEG is a safe and effective alternative for treating patients with juxtarenal aneurysms who have no other alternatives for repair. Longer-term follow-up is needed to assess the durability of repair and potential for device-related complications
A surgeon’s perspective regarding the regulatory, compliance, and legal issues involved with physician-modified devices
No full textPhysician-modified endovascular devices are becoming commonplace in a modern climate where innovation outpaces regulated technological advancement. Off-label use of medical devices occurs on a daily basis throughout many institutions across the United States and when performed by physicians, is both legal and unregulated. The purpose of this invited commentary is to review the regulatory, compliance, and legal issues regarding the practice of medical device modification
Heteropriacanthus carolinus
No full textHeteropriacanthus carolinus (Cuvier, 1829). Pacific Glasseye. To 51 cm (20 in) TL (Robertson and Allen 2002). Indo-Pacific; western Pacific Ocean north to Yonaguni-jima Island, Japan (Koeda et al. 2016); Santa Catalina Island, southern California (Walker et al. 2020); Isla Guadalupe, central Baja California (Grove and Lavenberg 1997) to Panama (Fricke et al. 2020), or perhaps Chile (Starnes 1988), and at least around Isla Cerralvo, Gulf of California (Galván-Magaña et al. 1996), and Islas Galápagos (Grove and Lavenberg 1997). Depth: intertidal to 300 m (984 ft) (min.: Personal communication: Scripps Institution of Oceanography Fish Collection, La Jolla, California; max.: Hureau in Quéro et al. 1990). We follow Fernandez-Silva and Ho (2017) and separate this species from the previously believed to be circumglobal Heteropriacanthus cruentatus (Lacepède, 1801).Published as part of Love, Milton S., Bizzarro, Joseph J., Cornthwaite, Maria, Frable, Benjamin W. & Maslenikov, Katherine P., 2021, Checklist of marine and estuarine fishes from the Alaska-Yukon Border, Beaufort Sea, to Cabo San Lucas, Mexico, pp. 1-285 in Zootaxa 5053 (1) on page 150, DOI: 10.11646/zootaxa.5053.1.1, http://zenodo.org/record/557800
Early report from an investigator-initiated investigational device exemption clinical trial on physician-modified endovascular grafts
No full textObjectiveTo determine whether a physician-modified endovascular graft (PMEG) is a safe and effective method for treating patients with juxtarenal aortic aneurysms who are deemed unsuitable for open repair.MethodsA nonrandomized, prospective, consecutively enrolling investigational device exemption clinical trial was used. Data collected on patients treated with PMEG between April 2011 and August 2012 were analyzed. Subjects were followed with computed tomography, visceral duplex, and four-view X-ray at 30 days, 6 months, and 1 year. The protocol was designed to include follow-up to 5 years. The primary safety end point was the proportion of subjects who experienced a major adverse event (MAE) within 30 days of the procedure. The primary efficacy end point was the proportion of subjects experiencing treatment success.ResultsDuring the 16-month study period, 28 patients were consented and 26 underwent endovascular repair using PMEGs. Anatomic, operative details, and length of stay were recorded and included aneurysm diameter (mean, 62.5 mm), proximal neck length (mean, 4.4 mm), graft manufacture time (mean, 59.7 minutes), procedure time (mean, 169 minutes), fluoroscopy time (mean, 42.8 minutes), total contrast usage (mean, 63 mL), estimated blood loss (mean, 221 mL), and length of hospital stay (mean, 4.9 days). There were 63 fenestrations created for 48 renal arteries and 15 superior mesenteric arteries. Renal artery fenestrations were stented whenever possible (96%) and superior mesenteric artery fenestrations were all left unstented. There were no unanticipated adverse device events, no MAEs, and only a single minor adverse device event treated with a successful reintervention. At 30 days, there were no type I or III endoleaks and only four type II endoleaks (15.4%). Two patients died during the study period, one at day 23 from respiratory failure (in-hospital and 30-day mortality = 3.8%) and one at day 210 from urosepsis and congestive heart failure. MAEs occurred in 11.5% of patients at 30 days. The primary efficacy end point was achieved in 87.5% of patients (technical success 100%, freedom from migration, rupture or conversion, type I or III endoleaks, or sac enlargement = 100%, 100%, 87.5%, and 87.5%, respectively).ConclusionsThese preliminary data suggest that endovascular repair with PMEG is safe and effective for managing patients with juxtarenal aortic aneurysms. Endovascular repair with PMEG has acceptable early rates of morbidity, mortality, and endoleak. This endovascular aortic strategy is particularly appealing for those patients presenting with symptomatic or ruptured aortic aneurysms until reliable off-the-shelf solutions become widely available
- …
